Efficacy and Safety of ABBV-154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo-Controlled Trial.

ABSTRACT:

Objective

Despite the availability of biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) to treat rheumatoid arthritis (RA), many patients do not experience optimized disease control. Glucocorticoids are effective but have safety risks. ABBV-154, an antibody-drug conjugate, is made up of adalimumab linked to a glucocorticoid receptor modulator. This phase 2b study evaluated the efficacy and safety of ABBV-154 in patients with moderately to severely active RA receiving background methotrexate with inadequate response to at least one prior b/tsDMARD.

Methods

Patients were randomized 1:1:1:1:1 to subcutaneous ABBV-154 40, 150, or 340 mg every other week; 340 mg every 4 weeks; or placebo. The primary endpoint was achieving 50% improvement in the A

SUBMITTER: Buttgereit F 

PROVIDER: S-EPMC12750116 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature